Novonesis (Novozymes) B (CHIX:NSISBC) E10: kr11.62 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NSISBC Novonesis (Novozymes) B CHIX:NSISBC
76 GF Score
Price kr425.45
GF Value kr428.67
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B E10?

Novonesis (Novozymes) B CHIX:NSISBC 76 E10 is kr11.62 as of Mar. 2026. GuruFocus rates CHIX:NSISBC with a GF Score™ of 76/100 and a GF Value™ of kr428.67 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted earnings per share data for the three months ended in Mar. 2026 was kr3.214. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr11.62 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novonesis (Novozymes) B's average E10 Growth Rate was -0.30% per year. During the past 3 years, the average E10 Growth Rate was 0.50% per year. During the past 5 years, the average E10 Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novonesis (Novozymes) B was 9.60% per year. The lowest was 0.50% per year. And the median was 7.35% per year.

As of today (2026-07-21), Novonesis (Novozymes) B's current stock price is kr425.45. Novonesis (Novozymes) B's E10 for the quarter that ended in Mar. 2026 was kr11.62. Novonesis (Novozymes) B's Shiller PE Ratio of today is 36.61.

During the past 13 years, the highest Shiller PE Ratio of Novonesis (Novozymes) B was 54.32. The lowest was 24.11. And the median was 38.72.


Novonesis (Novozymes) B  (CHIX:NSISBc) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novonesis (Novozymes) B's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=425.45/11.62
=36.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Novonesis (Novozymes) B was 54.32. The lowest was 24.11. And the median was 38.72.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novonesis (Novozymes) B E10 Related Terms


Novonesis (Novozymes) B E10 Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B E10 Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.57 22.01 11.59 11.66 11.50

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.56 11.59 11.47 11.50 11.62

CHIX:NSISBC vs LIN, SHW, ECL: E10 Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Shiller PE Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Shiller PE Ratio falls into.


CHIX:NSISBC
76GF Score
Novonesis (Novozymes) B CHIX:NSISBC
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novonesis (Novozymes) B's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.214/121.6800*121.6800
=3.214

Current CPI (Mar. 2026) = 121.6800.

Novonesis (Novozymes) B Quarterly Data

per share eps CPI Adj_EPS
201606 2.460 100.600 2.975
201609 2.479 100.200 3.010
201612 2.704 100.300 3.280
201703 2.580 101.200 3.102
201706 2.471 101.200 2.971
201709 2.770 101.800 3.311
201712 2.651 101.300 3.184
201803 2.726 101.700 3.262
201806 2.649 102.300 3.151
201809 2.757 102.400 3.276
201812 2.879 102.100 3.431
201903 2.407 102.900 2.846
201906 3.123 102.900 3.693
201909 2.230 102.900 2.637
201912 3.244 102.900 3.836
202003 2.883 103.300 3.396
202006 2.280 103.200 2.688
202009 2.527 103.500 2.971
202012 2.334 103.400 2.747
202103 3.150 104.300 3.675
202106 2.830 105.000 3.280
202109 3.011 105.800 3.463
202112 2.237 106.600 2.553
202203 2.980 109.900 3.299
202206 2.901 113.600 3.107
202209 4.143 116.400 4.331
202212 3.156 115.900 3.313
202303 2.818 117.300 2.923
202306 2.179 116.400 2.278
202309 3.363 117.400 3.486
202312 2.527 116.700 2.635
202403 0.597 118.400 0.614
202406 0.448 118.500 0.460
202409 2.535 118.900 2.594
202412 1.417 118.900 1.450
202503 2.983 120.200 3.020
202506 2.163 120.700 2.181
202509 2.239 121.600 2.240
202512 1.942 121.200 1.950
202603 3.214 121.680 3.214

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr11.62 mean?
Novonesis (Novozymes) B (CHIX:NSISBC) has a E10 of kr11.62 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's E10 too high?
Novonesis (Novozymes) B's current E10 is kr11.62. Overall, Novonesis (Novozymes) B has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's E10 compare to LIN and SHW?
Novonesis (Novozymes) B's E10 of kr11.62 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Chemicals company?
A good E10 depends on the Chemicals industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current E10 is kr11.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (CHIX:NSISBC) is currently considered Fairly Valued. The stock's GF Value™ is kr428.67, compared to a current price of kr425.45 — trading 0.8% below its estimated fair value. The current E10 is kr11.62. Novonesis (Novozymes) B's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Novonesis (Novozymes) B (CHIX:NSISBC), the current E10 is kr11.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (CHIX:NSISBC) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of kr425.45 is trading 0.8% below its estimated GF Value™ of kr428.67. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for CHIX:NSISBC:

  • E10: kr11.62
  • GF Value™: kr428.67 vs. price of kr425.45 (0.8% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the CHIX:NSISBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
76GF Score

Get the complete analysis for CHIX:NSISBC

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr425.45
Price
kr428.67
GF Value